1Rosenwald A,Wright G,Chan WC. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma[J].New England Journal of Medicine,2002,(25):1937-1947.doi:10.1056/NEJMoa012914.
2Fisher RI,Gaynor ER,Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin lymphoma[J].New England Journal of Medicine,1993,(14):1002-1006.doi:10.1056/NEJM199304083281404.
3Ohsawa M,Ikura Y,Fukushima H. Immunohistochemical expression of muhidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma[J].Oncology(Basel),2005,(4-6):422-431.
4Jazirehi AR,Huerta-Yepez S,Cheng G. Rituximab(chimeric anti-CD20 monoclonal antibody)inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines:role in sensitization to chemotherapeutic drug-induced apoptosis[J].Cancer Research,2005,(01):264-276.
5Lam LT,Davis RE,Pierce J. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling[J].Clinical Cancer Research,2005,(01):28-40.
6Uddin S,Hussain AR,Siraj AK. Role of phosphatidylinositol3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival[J].Blood,2006,(13):4178-4186.doi:10.1182/blood-2006-04-016907.
7Barancik M,Bohacova V,Sedlak J. LY294002,a specific inhibitor of P13K/Akt kinase pathway,antagonizes P-glycoprotein-mediated multidrug resistance[J].European Journal of Pharmaceutical Sciences,2006,(05):426-434.doi:10.1016/j.ejps.2006.08.006.
8Espinosa I,Bfiones J,Bordes R. Membrane PKC-beta 2protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma[J].Annals of Hematology,2006,(09):597-603.doi:10.1007/s00277-006-0144-y.
9Li S,Phong M,Lahn M. Retrospective analysis of protein kinase C-beta(PKC-beta)expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas[J].Biology Direct,2007,(01):8.doi:10.1186/1745-6150-2-8.
10Kurosu T,Takahashi Y,Fukuda T. p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide[J].Apoptosis:An International Journal on Programmed Cell Death,2005,(05):1111-1120.
8Tai YT,Chang BY,Kong SY,et al.Bruton's tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma[J].Blood,2012,120:1877-1887.
9Glassford J,Soeiro I,Skarell SM,et al.BCR targets cyclin D2 via Btk and the p85 alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells[J].Oncogene,2003,22:2248-2259.
10Baba Y,Nonoyama S,Matsushita M,et al.Involvement of wiskottaldrich syndrome protein in B-cell cytoplasmic tyrosine kinase pathway[J].Blood,1999,93:2003-2012.
